Curing cancer or curbing immigration: A question of national morality and priority

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul W. Thurman, DBA
Professor of management and analytics, Joseph L. Mailman School of Public Health, Columbia University Medical Center, Columbia University
Table of Contents

YOU MAY BE INTERESTED IN

Project Purple, a national nonprofit dedicated to empowering the fight against pancreatic cancer, is launching the Pancreatic Cancer Research Recovery Support Grant. The initiative provides up to two years of bridge or rescue funding for promising pancreatic cancer research projects that were disrupted due to administrative funding policy changes at major federal agencies such as the NIH, the Department of Defense, or the National Science Foundation. 
Paul W. Thurman, DBA
Professor of management and analytics, Joseph L. Mailman School of Public Health, Columbia University Medical Center, Columbia University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login